Clinical Significance of the Clopidogrel–Proton Pump Inhibitor Interaction After Peripheral Endovascular Intervention for Claudication

Abstract

Objective: Despite numerous studies in the cardiology literature, the clinical impact of proton pump inhibitor (PPI) administration on the antiplatelet effect of clopidogrel remains controversial. The objective of this study is to evaluate the effects of concurrent PPI and clopidogrel administration on outcomes after percutaneous transluminal angioplasty and stenting (PTA&S) of the superficial femoral artery (SFA) for claudication. Methods: Retrospective review of a prospectively maintained database (2004-2010) identified patients undergoing PTA&S of the SFA for lifestyle-limiting claudication (Rutherford Class III). Statistical analysis included univariate comparison (Wilcoxon, chi-square) of demographics, lesion characteristics, complication rates, and outcome measures. Patency comparisons were made with Cox-PH multivariable models and Kaplan-Meier survival analysis. Results: Totally, 109 limbs were treated in 103 patients. All were prescribed clopidogrel for 1 month; concurrent PPI use (+PPI) was identified after 42 (38.5%) interventions. There were no statistically significant differences in demographics, comorbidity prevalence, lesion length, degree of stenosis, or runoff associated with PPI use. There were no cases of early thrombosis in either group. There were more instances of patency loss (28 [50%] vs 21 [42%]; P = .40) in patients with +PPI, and a trend toward reduced primary patency that did not achieve statistical significance (P = .5). By multivariate analysis only TransAtlantic Inter-Society Consensus (TASC) D lesions were independent predictors of primary (hazards ratio [HR] = 4.366; [95% confidence interval (CI): 1.291-14.764; P = .018) and assisted patency loss (HR = 6.815 [1.181-39.327]; P = .032). Conclusions: The clinical significance of the clopidogrel-PPI interaction is a controversial topic that has been the subject of numerous studies in the cardiology literature. This is the first report to examine this medication interaction after peripheral intervention. While there is no apparent association between PPI coadministration with clopidogrel in this series, the high prevalence of PPI use among patients prescribed clopidogrel following peripheral intervention warrants ongoing attention to this purported medication interaction.

Keywords

peripheral endovascular outcomes

Get full access to this article

View all access options for this article.

References

Cuisset

Frere

Quilici

. Comparison of omeprazole and pantoprazole influence on a high 150 –mg clopidogrel maintenance dose: the PACA (Proton Pump Inhibitors and Clopidogrel Association) prospective randomized study. J Am Coll Cardiol. 2009;54(13):1149–1153.

Gilard

Arnaud

Cornily

. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51(3):256–260.

Maddox

Wang

. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937–944.

Gupta

Bansal

Sotos

Olden

. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci. 2010;55(7):1964–1968.

Ray

Murray

Griffin

. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med. 2010;152(6):337–345.

Banerjee

Weideman

. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol. 2011;107(6):871–878.

Tentzeris

Jarai

Farhan

. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcomes in patients after coronary stent implantation. Thromb Haemost. 2010;104(6):1211–1218.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm191169.htm. Accessed on 9/1/2011.

Rooke

Hirsch

Misra

. Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society for Vascular Medicine; Society for Vascular Surgery. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Vasc Med. 2011;16(6):452–476.

10.

Meltzer

Gallagher

Khan

. Congestive heart failure with systolic dysfunction is associated with decreased patency after endovascular intervention for symptomatic peripheral arterial disease. J Vasc Surg. 2012;55(2):353–362.

11.

Rutherford

Baker

Ernst

. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26(3):517–538.

12.

Bhatt

Cryer

Contant

. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 201;363:1909–1917.

13.

O'Donoghue

Braunwald

Antman

. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials. Lancet. 2009;374(9694):989–997.

14.

Harjai

Shenoy

Orshaw

Usmani

Boura

Mehta

. Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) Investigators. Circulation. 2011;4:162–170.

15.

Evanchan

Donnally

Binkley

Mazzaferri

. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol. 2010;33(3):168–171.

16.

Conrad

Cambria

Stone

. Intermediate results of percutaneous endovascular therapy of femoropopliteal occlusive disease: a contemporary series. J Vasc Surg. 2006;44(4):762–769.

17.

Bakken

Protack

Saad

. Impact of chronic kidney disease on outcomes of superficial femoral artery endoluminal interventions. Ann Vasc Surg. 2009;23(5):560–568.

18.

O'Brien-Irr

Dosluoglu

Harris

Dryjski

. Outcomes after endovascular intervention for chronic critical limb ischemia. J Vasc Surg. 2011;53(6):1575–1581.

19.

DeRubertis

Faries

McKinsey

. Shifting paradigms in the treatment of lower extremity vascular disease: a report of 1000 percutaneous interventions. Ann Surg. 2007;246(3):415–422.

20.

Dormandy

Rutherford

RB.

Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31 (1 pt 2): S1 S296.

21.

Norgren

Hiatt

Dormandy

Nehler

Harris

Fowkes

; TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5–S67.

22.

Peduzzi

Concato

Feinstein

Holford

. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48(12):1503–1510.